HOPKINTON, Mass., Aug. 31, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. (NASDAQ: CALP) today announced the availability of the IVIS Spectrum CT, a breakthrough preclinical imaging system that integrates, into a single instrument system, advanced optical imaging and low dose microCT (micro computed tomography). Spectrum CT enables simultaneous molecular and anatomical longitudinal studies, providing researchers with vital, unparalleled insights into complex biological systems in small animal models used to develop new, clinically translatable discoveries. A broad array of applications exist for the new instrument, with musculoskeletal, vascular, oncology, phenotyping, cardiovascular and respiratory disease among those areas particularly enabled by the integration of optical and microCT imaging.
The Spectrum CT expands upon the versatility and advanced optical features of the Caliper IVIS and Maestro platforms, the leading preclinical optical imaging technologies with over 1250 instruments placed worldwide. The system offers powerful, flexible and exquisitely sensitive optical molecular imaging integrated with complementary, ultra-fast, low-dose microCT anatomical imaging. Features include optical sensitivity capable of achieving detection of a few cells and 3-dimensional reconstructions of optical molecular bioluminescence and fluorescence signals, integrated with 3-dimensional anatomical microCT images. Designed for high-throughput, quantitative, non-invasive longitudinal analysis of large cohorts of animals, Spectrum CT enables new, clinically translatable insights. Regarding one example application, Lloyd Miller, MD., PhD., Assistant Professor at UCLA Departments of Medicine and Orthopaedic Surgery commented
|SOURCE Caliper Life Sciences, Inc.|
Copyright©2010 PR Newswire.
All rights reserved